Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989948 · ClinicalTrials.gov registry record · NA
Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA
A NA study of Aortic Aneurysm, Thoracoabdominal, sponsored by Yale University.
- Active
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT02989948: Active NA study of Aortic Aneurysm, Thoracoabdominal, sponsored by Yale University.
NCT02989948 is a NA study of Aortic Aneurysm, Thoracoabdominal that is active but no longer recruiting, run by Yale University. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02989948, a NA study of Aortic Aneurysm, Thoracoabdominal, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.
Primary Outcome
Percent of patients who survive 30 days following surgery
Conditions Studied
Interventions
- DEVICE Physician-modified aortic endograft
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2031-12-31 |
| Phase | NA |
What the registry record for NCT02989948 still lists
NCT02989948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Aortic Aneurysm, Thoracoabdominal appearing as the primary indexed condition, and to 1 intervention - of which Physician-modified aortic endograft is the first listed.
NCT02989948 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02989948 about?
NCT02989948 is a clinical study titled "Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA". The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effe...
What is the current status of trial NCT02989948?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2020-04-22. Estimated completion is 2031-12-31.
What conditions does trial NCT02989948 study?
This clinical trial studies the following conditions: Aortic Aneurysm, Thoracoabdominal.
What interventions are being tested in trial NCT02989948?
The interventions under investigation include: Physician-modified aortic endograft (DEVICE).
Who is sponsoring clinical trial NCT02989948?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02989948 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Aneurysm, Thoracoabdominal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02989948's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI